{
    "nct_id": "NCT03136185",
    "official_title": "A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis",
    "inclusion_criteria": "* >18 years of age\n* Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, or PPV-MF or PET-MF per the International Working Group for Myelofibrosis Research and Treatment\n* High or intermediate-2 risk disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receiving other treatments for the condition (with exceptions and time limits)\n* Major surgery in last 4 weeks, any surgery in the last 2 weeks\n* History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening\n* History of splenectomy\n* Current use of prohibited medications\n* A concurrent second active and nonstable malignancy\n* Known human immunodeficiency virus infection or active Hepatitis B or Hepatitis C virus infection\n* Other hematologic/biochemistry requirements, as per protocol\n* Use of an investigational agent within last 14 days\n* Pregnant or lactating females",
    "miscellaneous_criteria": ""
}